Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: four-year follow-up.
Dib N, Michler RE, Pagani FD, Wright S, Kereiakes DJ, Lengerich R, Binkley P, Buchele D, Anand I, Swingen C, Di Carli MF, Thomas JD, Jaber WA, Opie SR, Campbell A, McCarthy P, Yeager M, Dilsizian V, Griffith BP, Korn R, Kreuger SK, Ghazoul M, MacLellan WR, Fonarow G, Eisen HJ, Dinsmore J, Diethrich E. Dib N, et al. Among authors: dinsmore j. Circulation. 2005 Sep 20;112(12):1748-55. doi: 10.1161/CIRCULATIONAHA.105.547810. Circulation. 2005. PMID: 16172284
Feasibility and safety of autologous myoblast transplantation in patients with ischemic cardiomyopathy.
Dib N, McCarthy P, Campbell A, Yeager M, Pagani FD, Wright S, MacLellan WR, Fonarow G, Eisen HJ, Michler RE, Binkley P, Buchele D, Korn R, Ghazoul M, Dinsmore J, Opie SR, Diethrich E. Dib N, et al. Among authors: dinsmore j. Cell Transplant. 2005;14(1):11-9. doi: 10.3727/000000005783983296. Cell Transplant. 2005. PMID: 15789658 Free article. Clinical Trial.
One-year follow-up of feasibility and safety of the first U.S., randomized, controlled study using 3-dimensional guided catheter-based delivery of autologous skeletal myoblasts for ischemic cardiomyopathy (CAuSMIC study).
Dib N, Dinsmore J, Lababidi Z, White B, Moravec S, Campbell A, Rosenbaum A, Seyedmadani K, Jaber WA, Rizenhour CS, Diethrich E. Dib N, et al. Among authors: dinsmore j. JACC Cardiovasc Interv. 2009 Jan;2(1):9-16. doi: 10.1016/j.jcin.2008.11.003. JACC Cardiovasc Interv. 2009. PMID: 19463392 Free article. Clinical Trial.
The future of cell therapy for myocardial regeneration.
Dib N, Dinsmore J. Dib N, et al. Among authors: dinsmore j. Am Heart Hosp J. 2006 Summer;4(3):211-5; quiz 216. doi: 10.1111/j.1541-9215.2005.05508.x. Am Heart Hosp J. 2006. PMID: 16894260 Review.
Autologous skeletal myoblasts transplanted to ischemia-damaged myocardium in humans. Histological analysis of cell survival and differentiation.
Pagani FD, DerSimonian H, Zawadzka A, Wetzel K, Edge AS, Jacoby DB, Dinsmore JH, Wright S, Aretz TH, Eisen HJ, Aaronson KD. Pagani FD, et al. Among authors: dinsmore jh. J Am Coll Cardiol. 2003 Mar 5;41(5):879-88. doi: 10.1016/s0735-1097(03)00081-0. J Am Coll Cardiol. 2003. PMID: 12628737 Free article. Clinical Trial.
Stem cells and cardiac repair: a critical analysis.
Dinsmore JH, Dib N. Dinsmore JH, et al. J Cardiovasc Transl Res. 2008 Mar;1(1):41-54. doi: 10.1007/s12265-007-9008-7. Epub 2008 Jan 31. J Cardiovasc Transl Res. 2008. PMID: 20559957 Review.
Recommendations for successful training on methods of delivery of biologics for cardiac regeneration: a report of the International Society for Cardiovascular Translational Research.
Dib N, Menasche P, Bartunek JJ, Zeiher AM, Terzic A, Chronos NA, Henry TD, Peters NS, Fernández-Avilés F, Yacoub M, Sanborn TA, Demaria A, Schatz RA, Taylor DA, Fuchs S, Itescu S, Miller LW, Dinsmore JH, Dangas GD, Popma JJ, Hall JL, Holmes DR Jr; International Society for Cardiovascular Translational Research. Dib N, et al. Among authors: dinsmore jh. JACC Cardiovasc Interv. 2010 Mar;3(3):265-75. doi: 10.1016/j.jcin.2009.12.013. JACC Cardiovasc Interv. 2010. PMID: 20298983 Free article.
125 results